Nora Kim
Areas of focus: Medical and surgical weight loss, GLP-1 therapies, and evidence-based supplements.
152 articles on WeightFAQ
- GLP-1 medications
- bariatric surgery
- type 2 diabetes remission
- cardiovascular risk
- night eating syndrome
- sarcopenic obesity
About Nora Kim
Nora Kim is a WeightFAQ staff writer who translates clinical, surgical, and pharmacological weight-loss research into plain-English guidance. She covers the GLP-1 landscape — semaglutide, tirzepatide, and next-generation drugs — alongside bariatric surgery types, post-op nutrition protocols, and revision options. Her articles also address type 2 diabetes remission, cardiovascular risk, PCOS, fatty liver, night eating syndrome, sarcopenic obesity, and how common medications like antipsychotics, statins, and antidepressants affect weight. Nora writes for readers weighing serious clinical decisions and wanting a clear read on evidence, safety, cost, and realistic outcomes.
Articles by Nora Kim (152)
- GLP-1 Medications and Birth Control: What to Know (2026)
Tirzepatide (Zepbound, Mounjaro) carries a labeled interaction with oral contraceptives: use a non-oral method or a backup barrier method for 4 weeks after starting the drug and after each dose escalation. Semaglutide (Ozempic, Wegovy) does not carry the same labeled warning, but delayed gastric emptying still matters. Here is the per-drug guidance, the mechanism, and the practical patient conversation.
- GLP-1 Injection Technique: How to Give Yourself the Shot (2026)
A step-by-step guide to giving yourself a weekly GLP-1 injection: the 3 approved injection sites, needle length and technique, pen mechanics for Ozempic/Wegovy/Zepbound/Mounjaro/Saxenda and compounded vials, site rotation, and what to do about leaks, bleeding, and missed doses.
- Contrave vs Qsymia vs Phentermine: 3-Way Head-to-Head Weight Loss (2026)
Contrave, Qsymia, and Phentermine are the three most-used oral non-GLP-1 anti-obesity medications. Qsymia produces the most weight loss, Phentermine is the cheapest and fastest-acting, and Contrave uniquely addresses reward-driven eating — but each has a distinct safety profile that decides the fit for most patients.
- How to Switch GLP-1 Medications: Wegovy, Zepbound, Ozempic, Mounjaro
Switching between GLP-1 medications happens for four reasons: formulary changes, side effects, plateaus, and cost. This guide covers the specific cross-titration protocols for each common switch, safe washout intervals, what to expect for weight-loss stability, and the three switches that require restarting titration from scratch.
- Rybelsus vs Ozempic: Oral vs Injectable Semaglutide Head-to-Head (2026)
Rybelsus and Ozempic are the same molecule (semaglutide) in different delivery systems. PIONEER 4 showed the daily oral tablet is roughly equivalent to weekly injectable at their T2D doses, but the fasting-water rule and dosing ceiling make the real-world weight-loss picture more nuanced.
- Ozempic vs Mounjaro: Head-to-Head Efficacy, Cost, and Coverage (2026)
Ozempic and Mounjaro are both weekly T2D injections used off-label for weight loss. SURPASS-2 favored Mounjaro on both HbA1c and weight at 40 weeks, but insurance coverage, cash-pay pricing, and titration tolerability decide the answer for most patients.
- Wegovy vs Zepbound: Head-to-Head Efficacy, Cost, and Side Effects (2026)
Wegovy and Zepbound are the same class, different molecule. SURMOUNT-5 favored Zepbound on total weight loss and ≥15% response, but tolerability, insurance, and cash-pay pricing flip the decision for many patients in 2026.
- Saxenda vs Wegovy: Daily vs Weekly GLP-1 for Weight Loss (2026)
Saxenda and Wegovy are both Novo Nordisk GLP-1s FDA-approved for obesity — but semaglutide (Wegovy) roughly doubled the weight loss of liraglutide (Saxenda) in the STEP-8 head-to-head. Daily-vs-weekly injection frequency, insurance coverage, adolescent labeling, and the arrival of generic liraglutide all shape the actual choice in 2026.
- Managing GLP-1 Side Effects: A Practical Symptom-by-Symptom Guide (2026)
60–75% of GLP-1 patients get some GI side effect in the first 12 weeks; most are manageable with dose-timing, hydration, meal-composition, and short-term adjuncts, but a small percentage require dose-holds, down-titration, or discontinuation — this guide gives the specific thresholds and protocols.
- GLP-1s and Alcohol: Safety, Cravings, and Practical Guidelines (2026)
GLP-1s and alcohol have no strict contraindication, but three real interactions warrant care — pancreatitis risk, hypoglycemia risk in T2D combos, and dehydration — and emerging evidence suggests semaglutide may reduce alcohol cravings and heavy-drinking days.
- Weight Loss Blood Tests: The 12 Labs to Ask Your Doctor For (2026 Guide)
The core panel — HbA1c, fasting glucose, lipids, TSH, CBC, CMP, vitamin D — turns up the fixable medical reasons weight loss stalls. Here is the extended list, 2026 US cost, and when to add fasting insulin, ferritin, or a PCOS panel.
- Retatrutide vs Tirzepatide: How Lilly's Triple Agonist Compares to Zepbound
Retatrutide adds a glucagon receptor arm to tirzepatide's GLP-1/GIP dual mechanism, producing ~24% weight loss in Phase 2 vs tirzepatide's ~21% in SURMOUNT-1. Here is what is different, when retatrutide will actually be available, and whether it makes sense to wait.
- Mounjaro vs Zepbound: Same Drug, Two Brands, Different Insurance in 2026
Mounjaro and Zepbound are both tirzepatide from Eli Lilly, in the same pen at the same doses. The real differences are FDA indication, insurance coverage, and cash-pay pricing in 2026.
- VK2735 for Weight Loss: What Viking Therapeutics' Dual GLP-1/GIP Pipeline Actually Looks Like in 2026
VK2735 is Viking Therapeutics' investigational GLP-1/GIP dual agonist in both weekly injectable and daily oral forms. VENTURE-1 Phase 2 SC showed roughly 14.7 percent weight loss at 13 weeks. Here is what the trial actually said, the Phase 3 timeline, and why compounded 'VK2735' is not real.
- Petrelintide for Weight Loss: What Zealand Pharma's Amylin-Only Pipeline Actually Looks Like in 2026
Petrelintide (ZP8396) is Zealand Pharma's investigational long-acting amylin analog developed as a monotherapy for chronic weight management — the only amylin-only Phase 2 obesity asset in the world in 2026. Phase 1b dose-finding showed a dose-response from roughly 5 percent at low doses to roughly 8.6 percent at the top dose over 16 weeks. Petrelintide is not FDA-approved, is not commercially available, cannot be legitimately compounded, and the earliest realistic US availability is 2029 to 2030.
- Pemvidutide for Weight Loss: 15.6% at 48 Weeks in Altimmune's IMPACT Phase 2 (2026 Update)
Pemvidutide (ALT-801) is Altimmune's investigational once-weekly GLP-1/glucagon dual receptor agonist in Phase 2 for both obesity and MASH. The IMPACT Phase 2 trial (n=390, 48 weeks) reported roughly 15.6 percent placebo-adjusted weight loss at the 2.4 mg dose, plus a distinctive lipid signal (LDL, ApoB, and triglyceride reduction) and a 55–65 percent MRI-PDFF reduction in the hepatic sub-analysis. Pemvidutide is not FDA-approved, is not commercially available, cannot be legitimately compounded, and the earliest realistic US availability is 2029 to 2030. It is the last mid-stage watch-list drug in our next-generation pipeline map to receive a dedicated pillar.
- Oral GLP-1 Weight Loss Medications Compared: Rybelsus, Orforglipron, VK2735, and Oral Amycretin (2026)
Four oral GLP-1-class weight-loss medications — Rybelsus (approved), orforglipron (FDA action expected 2026–2027), VK2735 oral (Phase 1), and oral amycretin (Phase 1b) — compared on efficacy, dosing, fasting rules, tolerability, and 2026 US availability. Only Rybelsus is on pharmacy shelves; the practical 2026–2027 event to watch is the FDA decision on orforglipron.
- Survodutide for Weight Loss and MASH: −18.7% at 46 Weeks, FDA Breakthrough Status, and the Boehringer Pipeline
Survodutide (BI 456906) is a once-weekly dual GLP-1 / glucagon receptor agonist from Boehringer Ingelheim and Zealand Pharma in Phase 3 for both obesity and MASH. The Le Roux 2024 Phase 2b obesity trial reported roughly 18.7 percent mean weight loss at 46 weeks at the 4.8 mg dose, and the Sanyal 2024 Phase 2 MASH trial reported 63 percent MASH resolution and 65 percent fibrosis improvement at 48 weeks. FDA Breakthrough Therapy Designation was granted for MASH with F2 or F3 fibrosis in February 2024 — the first GLP-1 / glucagon dual to reach that milestone. Phase 3 SYNCHRONIZE obesity readouts are expected in mid-2026; realistic US availability is 2028 at the earliest.
- Mazdutide (Signifor) for Weight Loss: China Approval, GLORY-1 Data, and What US Patients Need to Know
Mazdutide (IBI362, brand name Signifor in China) is the first dual GLP-1 / glucagon receptor agonist approved anywhere in the world — China NMPA granted the label for both obesity and type 2 diabetes in June 2025. GLORY-1 reported roughly 14.4 percent mean weight loss at the 9 mg weekly dose at 48 weeks. Eli Lilly holds ex-China rights, an FDA filing is expected in 2027, and a realistic US launch is 2028 to 2029. There is no legal US access route today, and no compounded or overseas product on the 2026 market is real mazdutide.
- MariTide (Maridebart Cafraglutide): Monthly Weight-Loss Shot, Phase 3 Timeline, and What Makes GIP Antagonism Different
MariTide (maridebart cafraglutide, AMG 133) is Amgen's investigational monthly subcutaneous GLP-1 receptor agonist / GIP receptor antagonist bispecific for chronic weight management. In the MARITIME-2 Phase 2b trial (n=592, 52 weeks), the 420 mg loading-dose arm produced roughly −20.0% weight loss with no plateau at week 52, and the Phase 1b extension suggested ~70% of peak loss was retained 26 weeks after the last dose. The Phase 3 MARITIME-1 obesity trial fully enrolled Q3 2025 with a topline readout expected Q4 2026; realistic earliest US availability is late 2027 to 2028. It is not FDA-approved as of August 2026 and cannot be compounded — the bispecific antibody-peptide conjugate is not accessible to 503A pharmacies.
- Amycretin for Weight Loss: Novo's Amylin + GLP-1 Drug in Oral and Weekly Injection Forms
Amycretin is a single-molecule amylin + GLP-1 receptor agonist from Novo Nordisk in parallel Phase 2 development as a weekly subcutaneous injection and a daily oral tablet. Phase 1b results reported roughly 13.1 percent mean weight loss at 20 weeks with the SC formulation (Frías 2024, ADA) and roughly 13.1 percent at 12 weeks with the oral tablet (Rosenstock 2025, Lancet) — the most impressive short-timeframe weight-loss numbers reported for any obesity drug in development. Amycretin is not FDA-approved, is not commercially available, and the earliest realistic US availability is 2030.
- Orforglipron for Weight Loss: What Lilly's Oral GLP-1 Actually Delivers
Orforglipron is Eli Lilly's investigational once-daily oral GLP-1 receptor agonist and the first non-peptide, small-molecule drug in the class to complete Phase 3 obesity trials. The ATTAIN-1 topline reported roughly 12.4 percent placebo-subtracted weight loss at the 36 mg dose over 72 weeks — roughly Wegovy-tier magnitude in a pill with no fridge, no needle, and no empty-stomach or 30-minute water rule. Lilly filed the NDA in Q4 2025; a realistic FDA action window is Q3–Q4 2026, with commercial availability most likely 2027. It is not FDA-approved as of August 2026, and any product sold today as 'orforglipron' from a compounding pharmacy, telehealth peptide site, or overseas source is either counterfeit or research-chemical peptide.
- OMAD (One Meal A Day) for Weight Loss: Protocol, Evidence, Risks, Nutrient Density, and Honest Framing vs 16:8
OMAD (one meal a day) is a ~23-hour daily fast plus a 1-hour eating window at the extreme end of intermittent fasting. It produces weight loss primarily through the calorie deficit a 1-hour window naturally enforces, not through a unique metabolic mechanism. The direct RCT evidence is thin — Stote 2007 is the only true OMAD trial and it showed greater lean-mass loss versus a 3-meal comparator at matched calories — and the practical risks (nutrient inadequacy, glycemic spikes after a 23-hour fast, incompatibility with high training loads, contraindication in eating-disorder history) are real. This guide covers the protocol, the honest evidence base, contraindications, GLP-1 and antidiabetic-medication interactions, a nutrient-dense sample plate, six common OMAD mistakes, and a clear who-it-fits vs who-should-skip breakdown.
- Fasting-Mimicking Diet (ProLon): 5-Day Protocol, Real Evidence, Honest Verdict
Honest evidence review of the fasting-mimicking diet and ProLon — what the 5-day protocol looks like, what the Wei 2017 RCT actually showed, DIY approximation, and who it fits.
- Chromium Picolinate for Weight Loss: What 20+ Trials Actually Show
Chromium picolinate has one of the largest weight-loss RCT evidence bases of any supplement — 20+ trials pooled in the Onakpoya 2013 meta-analysis — and the placebo-subtracted effect lands at roughly 0.5 kg. This guide covers what the meta-analyses actually show, food sources, safety, dosing, the narrow T2DM use case, and honest verdicts on the marketing claims.
- Optavia (Medifast) Weight Loss Program: How the 5&1 Plan Works, Cost, Coach Structure, Evidence, and Honest Expectations
Optavia is the MLM-coach-network channel for Medifast's meal-replacement products. The flagship 5&1 Plan delivers roughly 800–1,000 kcal per day across five 100-kcal Fuelings plus one self-prepared Lean and Green meal, making it VLCD-adjacent. Published Medifast RCTs (Davis 2010, Cheskin 2008) show real 7–12% loss at 6 months driven by aggressive calorie restriction — the fastest short-term loss of any major commercial program. This guide covers the 5&1 protocol, 2026 pricing, the Medifast RCT evidence base, the MLM coach structure and its conflicts of interest, program comparisons, contraindications, and how to think honestly about staying on Optavia versus transitioning off.
- Hydration and Electrolytes for Weight Loss: Sodium, Potassium, Magnesium, GLP-1 Dehydration, Keto Flu, and Honest Supplement Framing
Aggressive calorie deficits, low-carb protocols, and GLP-1 medications all shift fluid and electrolyte balance in ways that produce the fatigue, headaches, cramps, and dizziness commonly misread as 'my plan is broken.' The fix is usually water plus a pinch of salt plus a potassium-rich food — not a $30-a-month electrolyte-packet subscription. This guide covers the physiology of glycogen-water displacement and low-carb natriuresis, target sodium and potassium and magnesium doses during weight loss, a practical keto-flu protocol, a GLP-1 sipping cadence, the evidence for electrolyte replacement, an honest look at LMNT / Element / Liquid IV / Nuun / DIY, and the contraindications that matter.
- CagriSema for Weight Loss: What Novo's GLP-1 + Amylin Combo Is, and Why You Can't Buy It Yet
CagriSema is Novo Nordisk's investigational once-weekly injection combining semaglutide 2.4 mg (the Wegovy molecule) with cagrilintide 2.4 mg, a long-acting amylin analog. In the REDEFINE-1 Phase 3 obesity trial it produced roughly 22.7 percent mean weight loss at 68 weeks. FDA submission is expected in 2026, with the earliest realistic pharmacy availability in 2027. It is not FDA-approved as of August 2026, and any product sold today as 'CagriSema' or a 'DIY cagri-sema stack' is illegally compounded or research-chemical peptide.
- Retatrutide for Weight Loss: What the Triple-Agonist Actually Is, and Why You Can't Buy It Yet
Retatrutide is Eli Lilly's investigational triple agonist (GLP-1 + GIP + glucagon) that produced roughly 24.2 percent mean weight loss at 48 weeks in the Jastreboff 2023 NEJM Phase 2 trial — the highest magnitude ever reported for an obesity drug. It is not FDA-approved, is not sold at any legitimate pharmacy, and Phase 3 primary readouts land in the 2026 to 2027 window. Anything labeled 'retatrutide' online today is unregulated compounded peptide, not the Lilly molecule from the trial.
- Probiotics for Weight Loss: Which Strains Have Evidence, Which Are a Waste of Money
Most probiotic supplements sold for weight loss do not have RCT evidence for the specific strain, dose, or formulation on the bottle. A small number of named strains — L. gasseri BNR17, B. lactis B420, and pasteurized Akkermansia muciniphila — have published effects that are real but modest (typically under 1 kg over 12 weeks). This guide names the strains that pass, the marketing formulas that do not, and how to choose a product if you decide to try one.
- Intuitive Eating for Weight Loss: What the Framework Is, What the Evidence Shows, and Where It Disappoints
Intuitive eating is a 10-principle non-diet framework built by two registered dietitians in 1995 — not a weight-loss program. The best-controlled research shows it improves psychological outcomes and cardiometabolic markers more reliably than the scale, and readers who choose intuitive eating expecting a specific pound goal are usually disappointed. This guide covers the 10 principles, what the Van Dyke 2014 and Warren 2017 reviews actually show, where intuitive eating outperforms dieting, where it disappoints, an honest 30-day protocol, and the special situations (GLP-1s, T1DM, BED, adolescents, post-bariatric, weight-class athletes) where the framework needs adaptation.
- Carnivore Diet for Weight Loss: Honest Evidence, Real Risks, and What Actually Happens
The carnivore diet — meat, eggs, and optionally dairy with zero plant food — produces rapid short-term weight loss for the same reasons any deep-elimination protocol does, but the durable-outcome, cardiovascular-safety, and long-term-nutrient evidence is missing. This guide covers what the diet actually is, what the Lennerz 2021 survey does and does not show, the four risks that matter most (LDL response, colorectal cancer signal, kidney load, micronutrient gaps), how it compares to keto and PSMF, and the honest way to run a bounded 30-day trial with baseline labs and pre-defined exit criteria.
- Protein-Sparing Modified Fast (PSMF): Clinical Protocol, Evidence, and Who It Is Actually For
The protein-sparing modified fast (PSMF) is a 6–12 week, 800-ish kcal, near-zero-carb-and-fat protocol built around a high protein floor to preserve lean mass. It is a real clinical tool with a 45-year evidence trail — and a real set of risks (electrolyte disturbance, gallstones, refeeding syndrome, arrhythmia) that make it inappropriate for most routine weight-loss goals. This guide covers what PSMF is and is not, the honest evidence, the mandatory safety envelope, and who it actually fits.
- Cold Exposure for Weight Loss: What Ice Baths and Cold Plunges Actually Do (2026)
Cold plunges activate brown fat and burn a modest 100–300 extra kcal per session — real physiology, but small compared to a walk. Here's what the evidence actually shows, the honest kcal ceiling, safety limits, and where cold exposure genuinely helps.
- Very-Low-Calorie Diets (VLCDs): Clinical Protocol, Evidence, and Who They Are Actually For
Very-low-calorie diets deliver 400–800 kcal/day under medical supervision and put roughly 46% of eligible adults with recent-onset type 2 diabetes into remission at one year (DiRECT). This guide covers who a VLCD is and is not for, the 12-week clinical protocol, medication adjustments, real safety risks, and how VLCDs compare to GLP-1s and bariatric surgery.
- Green Tea and EGCG for Weight Loss: What the Evidence Actually Shows
Green tea catechins produce roughly 1 kg of extra weight loss over placebo across 12-week trials — a small but real signal that Cochrane 2012 judged 'not clinically important' — and the safety window narrows fast above 800 mg/day of EGCG from concentrated extracts, which is where liver-injury case reports concentrate.
- Long COVID and Weight Changes: Why Weight Goes Up or Down and What Actually Helps
Bidirectional weight changes are common in Long COVID — driven by deconditioning, dysautonomia, appetite disruption, sleep disruption, and medication effects — and the evidence-based response is a pacing-first protocol rather than more exercise.
- Food Noise: What It Is, Why GLP-1s Quiet It, and What Helps If You're Not on One
Food noise is the intrusive, repetitive thinking about food that GLP-1s famously quiet — here is what it is, why the drugs reduce it, and what evidence-based habits help when medication is not an option.
- Berberine for Weight Loss: The 'Nature's Ozempic' Claim vs What the Evidence Shows
Berberine has real glycemic and modest weight-loss evidence — roughly 1.5 to 2 kg over 12 to 16 weeks in meta-analyses — but it is not comparable to GLP-1 medications and carries meaningful drug-interaction and hepatotoxicity risks that the 'nature's Ozempic' framing obscures.
- Shift Work and Weight Loss: How to Eat, Train, and Sleep on Night, Rotating, and 12-Hour Shifts
Shift work weight-loss playbook: protein-anchored pre-shift meal, one 10-14 hour eating window, blackout-bedroom day-sleep, and 5 practical night-shift meal templates.
- Night Eating Syndrome and Weight Loss: How to Recognize the DSM-5 Pattern, Distinguish It From Snacking or Bingeing, and Actually Treat It
Night Eating Syndrome affects 1.5% of adults and up to 14% of bariatric candidates. It's a DSM-5-recognized circadian eating pattern — distinct from binge eating or snacking. Sertraline 200 mg (Allison 2018) and CBT-NES have real evidence. Here's how to recognize it and what actually works.
- Cardiovascular Disease and Weight Loss: What SELECT, Look AHEAD, and the STEP-HFpEF Trials Actually Show About MACE, MI, and Stroke Risk
SELECT showed semaglutide 2.4 mg cut major cardiac events 20% in patients with heart disease and obesity. Look AHEAD did not hit its primary endpoint at group level, but ≥10% loss did. Here's what the trials actually show about weight loss and cardiovascular risk.
- Type 2 Diabetes Remission via Weight Loss: What DiRECT, DIADEM-I, and STAMPEDE Actually Show About the 15 kg Threshold
DiRECT put 46% of participants into remission at 1 year and 36% at 2 years with primary-care VLCD. Here's the ADA/EASD definition, the ~15 kg threshold, and how DIADEM-I and STAMPEDE fit.
- Leptin, Ghrelin, and Hunger Hormones: What Actually Drives Appetite While You're Losing Weight
Sumithran 2011 showed leptin stays low and ghrelin stays high for at least 12 months after a diet. Here's what the six appetite hormones actually do and how to work with, not against, them.
- The Diabetes Prevention Program (DPP): Why the 7% Weight Loss / 150 Minute Standard Still Works 22 Years Later
The Diabetes Prevention Program showed that a 7% body-weight loss plus 150 minutes/week of moderate activity cut incident type 2 diabetes by 58% in adults with prediabetes — nearly twice the reduction produced by metformin. Two decades of follow-up in the DPPOS, Finnish DPS, and Da Qing cohorts show the benefit holds. This guide covers who qualifies, how to enroll in a CDC-recognized National DPP, and how the program layers with metformin, GLP-1 medications, and bariatric surgery.
- Bariatric Post-Op Vitamin and Nutrition Protocol: The ASMBS 2020 Standard for Sleeve, Bypass, SADI, and Revisions
The ASMBS 2020 lifetime supplement stack after sleeve gastrectomy, gastric bypass, and duodenal switch — dose by procedure, timing rules, standardized labs, and when to go to the ER.
- Gut Microbiome and Weight Loss: What Firmicutes, Bacteroidetes, and Akkermansia Actually Do to Body Weight
The gut microbiome shifts modestly with body weight, but the popular story — that a probiotic pill or a Firmicutes-to-Bacteroidetes ratio predicts obesity — is not what the evidence supports. Diet diversity, prebiotic fiber, and fermented foods produce the largest reproducible microbiome changes, while probiotic supplements and fecal microbiota transplant show small, inconsistent effects on human body weight.
- Rybelsus (Oral Semaglutide) for Weight Loss: What the 3, 7, and 14 mg Tablets Actually Do to the Scale
Rybelsus is the tablet form of semaglutide — the same molecule as Ozempic and Wegovy, delivered orally with an absorption-enhancer called SNAC. At its 14 mg maintenance dose it produces roughly 4 to 4.5 percent weight loss, well below Wegovy's 15 percent, but it gained a 2025 FDA cardiovascular-risk-reduction indication (SOUL) and a higher-dose oral formulation for obesity (OASIS-4, 50 mg) is under FDA review. Rybelsus requires a strict fasting window and 4 oz of plain water, and it is not first-line for weight loss.
- Next Generation Weight Loss Drugs: Where Retatrutide, Orforglipron, CagriSema, Survodutide, and MariTide Actually Stand in 2026
The post-tirzepatide anti-obesity pipeline is real and the Phase 2 signals are extraordinary — retatrutide about 24 percent at 48 weeks, MariTide about 19.5 percent with monthly dosing, CagriSema about 22.7 percent, orforglipron about 14.7 percent orally, survodutide about 19 percent. But none of these five drugs is FDA-approved for chronic weight management as of publication and Phase 3 outcome data land between mid-2026 and 2028. Wegovy and Zepbound remain the standard of care in 2026, and unregulated research-chemical retatrutide sold online is not the drug from the trials.
- Insulin Therapy and Weight in Type 2 Diabetes: Why Basal Insulin Causes Weight Gain and How to Mitigate It
Basal insulin adds about 2 to 4 kg per year on average in type 2 diabetes — mostly visceral — through glucosuria recapture, defensive snacking against hypoglycaemia, and direct anabolic action. Modern ADA 2024 ordering pushes insulin to third or fourth line behind metformin, GLP-1 agonists, and SGLT2 inhibitors, and layering rather than substituting prevents most of the weight-gain trade-off.
- Continuous Glucose Monitors for Weight Loss: What Stelo, Lingo, Dexcom, and FreeStyle Libre Actually Tell You
A continuous glucose monitor measures interstitial glucose every 1 to 5 minutes. In type 2 and type 1 diabetes it clearly improves outcomes and is standard of care. For weight loss in adults without diabetes the RCT signal is small but real — roughly 1 to 2 kg over 3 to 6 months when paired with behavioural coaching. Stelo (Dexcom, OTC 2024) and Lingo (Abbott, US launch 2024) made CGMs mainstream, and glucose spikes in non-diabetics are mostly normal physiology, not a weight-loss failure signal.
- Saxenda (Liraglutide 3 mg) for Weight Loss: Where the First FDA-Approved GLP-1 Fits After Wegovy and Zepbound
Saxenda (liraglutide 3 mg) delivers roughly 6–8% weight loss over 56 weeks — the FDA benchmark that opened the modern obesity-drug era in 2014, but roughly 40% of what semaglutide 2.4 mg delivers and 30% of tirzepatide 15 mg. It remains the only GLP-1 FDA-approved for adolescents 12+ and holds a legitimate niche when Wegovy or Zepbound are unavailable, contraindicated, or uncovered.
- Resmetirom (Rezdiffra) for MASH: What the First FDA-Approved Fatty Liver Drug Means for Weight and Fibrosis
Resmetirom (Rezdiffra) is the first FDA-approved drug for MASH — the inflammatory stage of fatty liver disease. In MAESTRO-NASH, roughly 26 to 30 percent of adults achieved MASH resolution and 24 to 26 percent achieved fibrosis improvement at 52 weeks, versus about 10 to 14 percent on placebo. It is an additive, not a replacement, therapy — the 5 to 10 percent weight loss that reverses steatosis remains the foundation.
- Orlistat (Xenical, Alli) for Weight Loss: How the Only FDA-Approved Lipase Inhibitor Works and When It Still Makes Sense
Orlistat (Xenical prescription, Alli OTC) blocks about 30% of dietary fat absorption and delivers roughly 3–4 kg placebo-adjusted weight loss at one year — about a quarter of what Wegovy achieves and a fifth of Zepbound — but it is the only OTC option, the only weight-loss drug with no CNS profile, an FDA-approved pediatric option since 2003, and the only pharmacologic weight-loss drug with a four-year outcomes trial (XENDOS) showing a 37% relative reduction in progression to type 2 diabetes.
- Compounded Semaglutide and Tirzepatide in 2026: Safety, Legality, and Quality After the Shortage Ended
Compounded semaglutide and tirzepatide were legal during the 2022–2024 FDA shortages, but both drugs came off the shortage list in late 2024 and mass-produced compounded copies are no longer legal under Section 503A except for narrow clinical-need exceptions. Here is the honest 2026 picture on safety, legality, quality, and how to evaluate a compounding pharmacy.
- SGLT2 Inhibitors and Weight: What Jardiance, Farxiga, and Invokana Actually Do to the Scale
SGLT2 inhibitors — empagliflozin (Jardiance), dapagliflozin (Farxiga), canagliflozin (Invokana) — produce about 1.8 kg of placebo-adjusted fat-mass loss on average, roughly half of what a GLP-1 delivers. They earn first-line status in type 2 diabetes with heart failure or chronic kidney disease because of cardiorenal outcomes, not because of the scale.
- Qsymia (Phentermine-Topiramate) for Weight Loss: How the Combination Works and Why It Delivers More Than Phentermine Alone
Qsymia (phentermine-topiramate) delivers roughly 9–11% placebo-adjusted weight loss over 56 weeks — best-in-class of the pre-GLP-1 orals, about 80% of semaglutide 2.4 mg and roughly half of tirzepatide 15 mg — with a REMS teratogenicity program, a real cognitive burden inherited from topiramate, and a DEA Schedule IV constraint inherited from phentermine.
- Menopausal Hormone Therapy and Weight: What Estrogen Does to Body Composition
Menopausal hormone therapy is not a weight-loss drug — but it also does not meaningfully cause weight gain. What the trials actually show on estrogen, body composition, T2D risk, and the timing hypothesis that reframed the WHI.
- Contrave (Naltrexone-Bupropion) for Weight Loss: What It Does, Who It Fits, and Where It Falls Short
Contrave (naltrexone-bupropion) delivers roughly 5–6% placebo-adjusted weight loss over 56 weeks — clinically useful, roughly half of semaglutide 2.4 mg and one-third of tirzepatide 15 mg — with a real seizure risk, an opioid-antagonism liability, and a boxed suicidal-behaviour warning inherited from bupropion.
- TRT and Weight: Fat Mass, Lean Mass, and What TRAVERSE Changed
Testosterone replacement therapy is a body-composition-shift drug, not a weight-loss drug. Expect roughly 1.7 kg of fat loss and 1.9 kg of lean-mass gain in confirmed hypogonadism — and after TRAVERSE 2023, the older heart-safety concern no longer holds in typical hypogonadal men.
- Statins and Weight: What They Do, What They Don't, and Who Should Be On One
Statins do not meaningfully cause weight gain. The muscle-symptom scare is largely nocebo, the diabetes signal is small, and the mortality benefit is real. What the trial evidence actually says — and why do not stop your statin because you lost weight.
- Metformin and Weight: What It Does, What It Doesn't, and When It Helps
Metformin is not a weight-loss drug. It produces about 2 to 3 kg of placebo-adjusted weight loss on average, plateaus by six months, and comes back on discontinuation — but it earns its place in prediabetes, PCOS, antipsychotic add-on, and type 2 diabetes for very specific reasons.
- Beta Blockers and Weight: Why the Scale Creeps and What Actually Helps
Beta blockers cause a small but real weight gain — about 1 to 2 kg on average — through suppressed thermogenesis and blunted lipolysis. The effect is drug-specific: propranolol and atenolol are the worst; carvedilol is intermediate; nebivolol is essentially weight-neutral. Do not stop your beta blocker to fix the scale.
- Opioids and Weight Changes: Chronic Pain, Long-Term Use, and What Helps
Long-term opioids don't reliably drive scale weight, but three linked mechanisms do — endocrine, constipation, and de-conditioning — while methadone maintenance adds 5 to 15 kg. The honest picture and what actually helps.
- Breast Cancer Survivor Weight: Aromatase Inhibitors, Tamoxifen, and What Helps
Adjuvant endocrine therapy drives 2 to 5 kg of survivor weight gain over 5 to 10 years — mostly via joint pain, activity loss, and treatment-induced menopause. The honest picture and what actually helps, always alongside your oncology team.
- Dumping Syndrome After Bariatric Surgery: Early, Late, and What Helps
Early dumping is sweats and cramps after meals. Late dumping is hypoglycemia 1–3 hours later. The honest food, drug, and re-operation picture.
- Antipsychotics and Weight Gain: Olanzapine, Clozapine, and What Helps
Antipsychotics vary widely in weight effect. Olanzapine and clozapine drive the most; aripiprazole and lurasidone the least. The honest drug-by-drug picture and what actually helps.
- Corticosteroids and Weight Gain: What Prednisone Does and What Helps
Prednisone causes weight gain through appetite, fluid, and central fat. The honest dose-time picture, what actually helps, and when to ask for a taper.
- Weight Loss for Older Adults: BMI, Function, Honest Playbook
After 65, BMI rules shift, muscle and bone come first, and faster isn't safer. The honest function-first playbook for losing weight as you age.
- Hyperthyroidism and Weight Loss: Graves', Treatment, Rebound
Hyperthyroidism speeds weight loss — and most patients regain past baseline once treated. What causes the loss, the rebound, and what helps.
- Lupus (SLE) and Weight Loss: Steroids, Flares, and What Helps
Most lupus weight gain is driven by steroids and flare cycles, not the disease itself. What hydroxychloroquine, biologics, diet, and exercise actually change.
- Hypoglycemia and Weight Loss: Spot, Treat, and Prevent It
Low blood sugar is the most common safety issue in weight-loss care. Insulin, GLP-1, post-bariatric, fasting — what helps, what doesn't.
- Cushing's Syndrome and Weight Gain: Symptoms, Tests, What Helps
Cushing's is rare but real. The symptoms, how it's diagnosed, and what actually helps the iatrogenic and endogenous forms.
- Type 1 Diabetes and Weight Loss: Insulin, CGM, and What Helps
Intensive insulin therapy adds 4–5 kg in T1D. CGM, hybrid closed-loop, metformin, and exercise tactics that work without hypoglycemia.
- Sarcopenia and Weight Loss: How to Protect Muscle as You Age
Sarcopenia speeds up after 60 and accelerates on GLP-1s. Protein, resistance training, and what actually preserves muscle through weight loss.
- Multiple Sclerosis and Weight Loss: Diet, Steroids, Plan
MS, steroids, and DMTs reshape weight in ways generic plans miss. Diet, mobility-aware exercise, and what actually helps.
- Psoriatic Arthritis and Weight Loss: How Body Weight Changes PsA
Obesity reduces biologic response in PsA. A 16% weight loss produced ACR responses without drug change. Here is the evidence and a 5-step plan.
- Low Testosterone and Weight Loss: TRT vs Weight Loss
Visceral fat lowers testosterone and weight loss raises it. Evidence on when TRT helps, when it doesn't, and a 5-step plan.
- Hashimoto's Thyroiditis and Weight Loss: TSH, Diet, and What Helps
Hashimoto's is the #1 cause of hypothyroidism. Treatment, diet, and TSH targets that actually move the scale — without the supplement myths.
- Prediabetes and Weight Loss: How a 7% Loss Cuts Diabetes Risk in Half
About 96M US adults have prediabetes. A 5–7% weight loss cuts type 2 diabetes risk by ~58%. Here is the evidence and a 5-step plan.
- Lymphedema and Weight Loss: What Actually Helps Swelling
Weight loss can meaningfully reduce lymphedema swelling. Here is what the evidence says about diet, exercise, compression, and surgery.
- IBD and Weight Loss: Crohn's, Ulcerative Colitis, and What Helps
Obese-IBD blunts biologic response. Here is the diet, dosing, and GLP-1 evidence plus a 5-step plan from a clinician's lens.
- Rheumatoid Arthritis and Weight Loss: Treatment Response
Obesity blunts RA biologic response by ~40%. Here is the link, a 5-step plan, and what bariatric and GLP-1 evidence shows.
- Osteoporosis and Weight Loss: Protect Your Bones While You Lose
Aggressive weight loss can cost bone. Here is the dose-response, a 5-step bone-protection protocol, and when to ask for a DEXA.
- IIH and Weight Loss: How Losing Weight Reverses Pseudotumor Cerebri
IIH is the most clearly weight-driven neurology condition. Here is the Sinclair RCT, IIHTT data, and what 5–10% loss can do for headache and vision.
- Hidradenitis Suppurativa and Weight Loss: How Losing Weight Reduces Flares
Obesity is one of the strongest drivers of HS flares. Here is the dose-response, a 5-step plan, and what bariatric and GLP-1 data show.
- COPD and Weight Loss: When to Lose, When to Gain, What Helps
COPD weight management is U-shaped: obesity worsens dyspnea; cachexia worsens survival. Here is the honest framework and what each scenario needs.
- Psoriasis and Weight Loss: How Losing Weight Clears Skin
Obesity worsens psoriasis. Here is the dose-response, a 5-step protocol, and what the low-energy-diet RCT and GLP-1 cohorts actually show.
- Pancreatitis and Weight Loss: GLP-1 Safety and Gallstone Risk
Ozempic and Mounjaro carry a pancreatitis warning. Here is what the trial data show, the gallstone-pancreatitis link, and a 5-step safety protocol.
- Migraine and Weight Loss: How Body Weight Affects Headaches
Obesity raises chronic migraine risk 5×. Here is the dose-response, a 5-step prevention protocol, and what topiramate and GLP-1 data show.
- Lipedema and Weight Loss: How to Tell It Apart From Obesity
Lipedema is a distinct lymphatic-fat disorder, not obesity. Here is how to tell them apart and the conservative-care ladder that actually helps.
- Dementia, Alzheimer's, and Weight Loss: What Body Weight Has to Do With Your Brain
Midlife obesity raises dementia risk ~70%. Here is the dose-response, a 5-step brain-protection protocol, and what GLP-1 and lifestyle data show.
- Stroke and Weight Loss: Cutting Risk Before and After a Stroke
Body weight is a leading modifiable stroke risk factor. Here is the dose-response, a 5-step prevention protocol, and what GLP-1 and bariatric data show.
- Metabolic Syndrome and Weight Loss: Reverse All 5 Markers
Losing 7 percent body weight reverses metabolic syndrome in about half of adults. Here is the ATP III diagnosis, the dose-response, and the 5-step protocol.
- Atrial Fibrillation and Weight Loss: 10% Loss Can Reverse AFib
Losing 10 percent of body weight makes adults 6 times more likely to stay AFib-free. Here is the dose-response, the 5-step protocol, and what GLP-1 data show.
- Asthma and Weight Loss: Better Breathing and Fewer Attacks
Obesity is a top risk factor for adult-onset asthma. Here is the dose-response, a 5-step protocol, and what bariatric and GLP-1 data show.
- Ozempic Face: Why GLP-1 Weight Loss Changes Your Face
Ozempic face is normal facial-fat loss made faster. Here's why it happens, who's most at risk, and how to prevent or treat it honestly.
- Heart Failure and Weight Loss: How Much to Lose to Help Your Heart
Modest weight loss improves symptoms in HFpEF, and GLP-1 medications now have direct trial data. Here is the dose-response, protocol, and obesity paradox explained.
- Cancer and Weight Loss: How Body Weight Drives Cancer Risk
Obesity raises risk for 13 cancers and is the second-leading preventable cause in the US. Here is the dose-response, prevention protocol, and bariatric and GLP-1 data.
- Gout and Weight Loss: Why Rapid Loss Can Trigger Attacks
Long-term weight loss cuts gout risk by 30 to 50 percent, but rapid loss can trigger attacks. Here is how to lose weight without flaring.
- Erectile Dysfunction and Weight Loss: How 10% Restores Function
Losing 5 to 10 percent of body weight reverses ED in roughly 1 in 3 men with obesity. Here is the protocol, the timeline, and what GLP-1 medications change.
- Chronic Kidney Disease (CKD) and Weight Loss: How Much to Lose to Protect Your Kidneys
Losing 5–10% of body weight slows CKD progression and lowers proteinuria. Here's how much to lose, and how semaglutide changes the math.
- Back Pain and Weight Loss: How Much to Lose to Cut Low Back Pain
Losing 5 to 10 percent of body weight cuts lower back pain in most adults. Here is how much to lose, why it works, and the 5-step protocol.
- Knee Osteoarthritis and Weight Loss: How Much to Lose to Cut Pain
Each pound lost takes about 4 pounds of force off your knees during walking. Here is how a 5 to 10 percent loss plus the right exercise cuts arthritis pain 30 to 50 percent.
- GERD and Weight Loss: How Much to Lose to Calm Heartburn
A 5 to 10 percent body-weight loss cuts reflux symptoms in roughly 80 percent of people. Here is the BMI dose-response, the 6-step protocol, and the sleeve-vs-bypass decision that quietly changes the answer.
- Gallstones and Weight Loss: Why Rapid Loss Triggers Them and How to Prevent Them
Rapid weight loss can trigger gallstones in 10 to 25 percent of people. Here is why it happens, who is at highest risk, and the 5 evidence-based steps that prevent them.
- Weight Loss and Cholesterol: LDL Drops ~2 mg/dL Per Kilogram (2026)
Every kilogram of weight lost drops LDL by ~2 mg/dL and triglycerides by ~7 mg/dL. See the 5–10% threshold, GLP-1 lipid data, and statin decision matrix.
- Sleep Apnea (OSA) and Weight Loss: Why It Matters and How Much to Lose
Obstructive sleep apnea affects an estimated 1 in 4 adults with overweight or obesity and worsens with weight gain — and weight loss is one of the few interventions that genuinely improves it. Here is what OSA is, how it is diagnosed, how much weight loss reduces it, and what the new GLP-1 / tirzepatide data really shows.
- Fatty Liver Disease (NAFLD / MASLD) and Weight Loss: How Much You Need to Lose to Reverse It
Fatty liver disease (renamed MASLD in 2023) affects roughly 1 in 3 US adults and is silently driven by excess body fat, insulin resistance, and added sugar. The good news: a 5 to 10 percent body-weight loss reverses the fat in most people, and a 10 percent loss reverses fibrosis in many. Here is what the disease actually is, how it is diagnosed, and the evidence-based weight-loss path that works.
- High Blood Pressure and Weight Loss: How Much to Lose to Drop Your Numbers
Weight loss is one of the most reliable non-drug ways to lower blood pressure: roughly 1 mmHg of systolic drop per kilogram lost, with a 5 to 10 percent body-weight loss often enough to drop a stage. Here is what the evidence shows, the 5-lever protocol that works, and how to think about medications and DASH.
- GLP-1 Microdosing: What It Is, Who Does It, and What the Evidence Says
GLP-1 microdosing uses 1/4 to 1/8 of the labeled semaglutide or tirzepatide dose, usually for cost, side-effect tolerance, recomposition, or maintenance. Here's what the evidence actually shows, what it does not, and how to think about it honestly in 2026.
- Constipation During Weight Loss: Causes, Fixes, and When to See a Doctor
Constipation during weight loss usually comes from one of four causes — less food volume, less fiber, less water, or slower gut motility from a GLP-1 — and resolves with a 5-step protocol. Most cases don't need a laxative; some need a doctor.
- Rebound Weight Gain After Stopping GLP-1: What to Expect and How to Minimize It
In the STEP-1 extension, patients regained about two-thirds of lost weight within 1 year of stopping semaglutide — but planned tapering, lifestyle anchoring, and maintenance dosing each meaningfully change the outcome.
- Insulin Resistance and Weight Loss: How to Recognize It and What Actually Reverses It
Insulin resistance is the most common metabolic reason adults struggle to lose weight. This guide explains how to recognize it, how it is tested, and the four evidence-based approaches that reliably reverse it.
- Set Point Theory: Why Your Body Defends a Higher Weight (and What To Do About It)
Your body actively defends a 'set point' weight through metabolic and hunger changes. This guide explains the leptin and ghrelin biology, what shifts the set point downward (slowly), and what doesn't.
- Menopause and Weight Loss: What Changes and What to Do About It
Menopause shifts where fat is stored and slows muscle maintenance; here's what actually changes, what doesn't, and the realistic playbook for losing weight through perimenopause and beyond.
- GLP-1 Cost and Insurance Coverage in 2026: Ozempic, Wegovy, Mounjaro, Zepbound
What GLP-1 weight loss medications actually cost in 2026, what insurance covers, manufacturer savings programs, compound vs brand pricing, and how telehealth changes the math.
- Diabetes and Weight Loss: A Type 2 Reversal-Focused Guide
Type 2 diabetes responds strongly to weight loss; this guide explains the remission thresholds, what to eat, how GLP-1 medications and metformin fit in, and what to expect realistically.
- Thyroid and Weight Loss: What Hypothyroidism Actually Does to Your Metabolism
Untreated hypothyroidism modestly lowers resting metabolism — roughly 5 to 10 percent, not the ruined-metabolism myth — and once TSH is in range on levothyroxine, weight loss follows normal diet-and-exercise rules.
- PCOS and Weight Loss: A Realistic, Evidence-Based Guide
PCOS makes weight loss harder through insulin resistance and androgen excess, but a 5–10% body-weight loss meaningfully improves cycles, fertility, and metabolic markers — here is what actually works for diet, exercise, sleep, and medication.
- Body Fat Percentage: How to Measure It and Healthy Ranges
What body fat percentage actually means, healthy ranges by age and sex, how to measure it accurately at home or in a clinic, and why it complements (but doesn't replace) BMI.
- Non-Surgical Weight Loss Procedures Compared: ESG vs Gastric Balloon vs Gastric Band
Side-by-side comparison of endoscopic sleeve gastroplasty (ESG), intragastric balloon, and adjustable gastric banding — expected weight loss, reversibility, recovery, BMI eligibility, and how to choose.
- Bariatric Surgery vs GLP-1: Cost, Weight Loss %, and When Each Wins
An honest, evidence-based comparison of bariatric surgery and GLP-1 medications — average weight loss, durability, cost, side effects, and who each is best for.
- Bariatric Surgery Cost and Insurance Coverage: What Weight Loss Surgery Really Costs
What gastric bypass, sleeve, band, ESG, and gastric balloon actually cost in the U.S. — self-pay ranges, what insurance covers, BMI requirements, the approval timeline, and how to handle a denial.
- GLP-1 Weight Loss Medications Compared (2026): Ozempic vs Wegovy vs Mounjaro vs Zepbound
Head-to-head comparison of Ozempic, Wegovy, Mounjaro, and Zepbound — average 15–22% body-weight loss at 68–72 weeks, dosing schedules, side-effect profiles, and 2026 U.S. list prices.
- Bariatric Surgery Types Compared (2026): Gastric Bypass vs Sleeve vs Band vs ESG
Side-by-side comparison of gastric bypass, sleeve, band, ESG, balloon, and revision — typical 1-year weight loss ranges from 10% to 30% of total body weight, with reversibility, recovery time, and cost.
- Mounjaro for Weight Loss: 15-21% Loss in 72-Week Trials
Mounjaro (tirzepatide) is a prescription GIP/GLP-1 injection that produced 15-21% average weight loss over 72 weeks in the SURMOUNT trials.
- Best Natural Appetite Suppressant: What Actually Works
The best natural appetite suppressant is glucomannan fiber — backed by clinical trials. Stimulants fade fast and none match prescription GLP-1s.
- Zepbound for Weight Loss: Cost, Results, Side Effects
Zepbound (tirzepatide) for chronic weight management: average results, monthly cost, side effects, candidacy, and how it compares to other GLP-1 drugs.
- Ozempic vs Wegovy: Key Differences Explained
Ozempic vs Wegovy: same molecule (semaglutide) at different max doses—2 mg (T2D) vs 2.4 mg (weight loss). Cost, coverage, and side effects.
- Endoscopic Sleeve Gastroplasty: Procedure & Eligibility
Who qualifies for endoscopic sleeve gastroplasty (ESG)? BMI criteria, candidacy rules, expected results, costs, and how it compares to bariatric surgery.
- Ozempic for Weight Loss: What to Know
Ozempic (semaglutide) for weight loss — how the diabetes GLP-1 works off-label, expected results vs Wegovy, side effects, cost, and safety.
- Loose Skin After Weight Loss: What Actually Helps (2026)
Loose skin after losing 50+ pounds is common — here's what actually helps tighten it, what doesn't, and when body-contouring surgery makes sense.
- Wegovy for Weight Loss
Wegovy (semaglutide 2.4 mg) for chronic weight management — how it works, ~15% STEP-1 loss at 68 weeks, side effects, cost, and rebound risk.
- Semaglutide vs Tirzepatide
Semaglutide vs tirzepatide: ~14.9% vs ~20.9% avg loss in pivotal trials, plus SURMOUNT-5 head-to-head, cost, side effects, and who each fits.
- Weight Loss Supplements Overview
Weight-loss supplements almost never cause meaningful weight loss on their own — most trials show < 1 kg over placebo. Here is the evidence tier by category (fiber, protein, caffeine, green-tea extract, berberine, creatine, ACV), what to avoid, and the four supplements worth considering.
- Weight Loss Injections Near Me
Learn what people mean by weight loss injections, how local and telehealth options differ, and what questions to ask a provider.
- Weight Loss Drug Safety
Weight loss drug safety — GLP-1s, phentermine, Contrave, and Qsymia carry different risks. Side effects, monitoring, and red flags in one guide.
- Tirzepatide for Weight Loss
Tirzepatide is a dual GIP/GLP-1 medication that supports weight loss; explore benefits, risks, and expectations.
- Sleeve Gastrectomy
Sleeve gastrectomy removes about 80% of the stomach, produces roughly 25% total-body-weight loss at one year, and works partly by dropping the hunger hormone ghrelin — here's who qualifies, what recovery looks like, and how it compares to gastric bypass and GLP-1 medications.
- Semaglutide for Weight Loss
Semaglutide for weight loss: ~14.9% avg loss in STEP-1 at 68 weeks. Dosing, safety, cost, and how it compares to tirzepatide.
- Prescription Weight Loss Medications
Prescription weight loss medications — GLP-1s, phentermine, Qsymia, Contrave, and orlistat — compared on efficacy, cost, side effects, and fit.
- Phentermine for Weight Loss
Phentermine is a DEA Schedule IV appetite suppressant that produces roughly 5–10% weight loss over 12 weeks — still the most-prescribed oral obesity drug in the US in 2026 because it costs $15–$40 a month generic. Here is who it fits, the 12-week-rule reality, how it stacks up against GLP-1s, and the cardiovascular monitoring that has to come with it.
- Ozempic Side Effects: Common Side Effects and Adverse Effects
A clear guide to the common side effects of Ozempic—nausea, vomiting, diarrhea, constipation, abdominal pain, and decreased appetite—and the more serious adverse effects to watch for, including pancreatitis, gallbladder disease, and kidney injury.
- Medical Weight Loss Programs
Physician-supervised weight-loss programs pair medical monitoring (labs, meds, comorbidity screening) with structured lifestyle support. Here is what in-person vs telehealth vs hybrid programs actually cost in 2026, what evidence supports each, and how to pick one.
- GLP-1 Weight Loss Medications Overview
GLP-1 weight loss medications — semaglutide, tirzepatide, and the newer options — deliver 15–22% average loss in trials. Here's how they work, who they fit, and what to expect.
- Gastric Bypass Surgery
Learn how Roux-en-Y gastric bypass works, who it is for, and what to expect before and after surgery.
- Gastric Balloon Procedures
Gastric balloons are temporary devices that help reduce appetite and portion sizes; learn the pros and cons.
- Fat Burner Supplements: What Works, What Doesn't, and What's Dangerous
Fat-burner supplements are a mixed bag — caffeine, green tea EGCG, and protein/fiber have modest documented effects, while synephrine, yohimbine, and DMAA carry real cardiovascular risks and roughly 20–70% of tested weight-loss supplements contain undeclared drugs, so evidence-tier and third-party testing matter more here than in most supplement categories.
- Bariatric Surgery Revision
Bariatric surgery revision is a second procedure done for inadequate weight loss, regain, or complications like severe reflux — it carries higher risk than a first surgery, so most 2026 protocols try GLP-1 medications, behavioral therapy, or endoscopic options before returning to the OR.
- Bariatric Surgery Overview
Bariatric surgery — sleeve, bypass, revision — delivers the largest, most durable weight loss when meds aren't enough. Who qualifies and what it costs.
- Adjustable Gastric Banding in 2026: Cost, Results, and Removal Options
How the adjustable gastric band (lap band) works in 2026: typical 15–20% weight loss, cost, insurance, side-by-side comparison with sleeve and bypass, and what to do if you already have one.